Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses - PubMed
3 hours ago
- #CAR T cell therapy
- #autoimmune diseases
- #allogeneic immunotherapy
- The study presents an allogeneic dual CAR T cell therapy combining a CD19 CAR for targeting B cell malignancies and autoimmune diseases with a CD70 CAR to prevent rejection by targeting activated alloreactive lymphocytes.
- Co-expression of CD19 and CD70 CARs resulted in sustained persistence of CAR T cells in the presence of alloreactive lymphocytes and prolonged antitumor activity in a CD19 antigen escape model.
- In humanized mouse models, CD19/CD70 dual CAR T cells eliminated B cells and CD70+ T cells from patients with systemic lupus erythematosus, reducing immunoglobulin production.
- This approach may broaden the clinical applicability of allogeneic CAR T cells and allow for less intensive lymphodepletion regimens prior to infusion.